Haleon, the U.S.-based unit of the U.K.-based global consumer health company, has issued a recall for their Robitussin cough syrup sold nationwide. The recall comes after the discovery of microbial contamination, which poses a potential risk of deadly infections, particularly for individuals with impaired immune systems. The company expressed concern that the use of the recalled products could result in severe or even life-threatening fungal infections.

According to a notice posted by the Food and Drug Administration (FDA), while most users are unlikely to experience serious health problems, there is still a possibility of developing an infection that may require medical intervention. As a precautionary measure, Haleon strongly advises consumers who have purchased the affected products to refrain from using them.

Haleon has provided a helpline for customers who seek further information or assistance. They can contact the company at (800) 245-1040 during weekdays, from 8 a.m. to 6 p.m. Eastern time, or email mystory.us@haleon.com.

The recall announcement serves as a reminder of the importance of product safety and quality control in the pharmaceutical industry. Haleon's swift action to alert the public about the contamination issue demonstrates their commitment to ensuring consumer well-being.

As of now, no specific numbers or dates related to the recall have been mentioned. However, it is crucial for consumers to stay informed and take appropriate steps if they have purchased the affected Robitussin cough syrup. Customers are advised to reach out to Haleon for more details regarding product returns or reimbursements.

It is recommended that consumers thoroughly check their medicine cabinets and discard any products included in the recall. Health authorities will continue to monitor the situation closely and provide updates as necessary to safeguard public health.